Literature DB >> 795576

Leukocyte migration inhibitory factor (LMIF) profile in primary and secondary immunodeficiency disease.

A J Górski, B Dupont, J A Hansen, R O'Reilly, E Smithwick, R Górska, R A Good.   

Abstract

Lymphocytes from patients with primary and secondary immunodeficiency disease were tested for capacity to produce LMIF after mitogen and antigen stimulation as well as for ability to stimulate and respond in unidirectional MLC-LMIF assay. Different patterns of immune abnormality in vitro were detectable when Con A and Candida albicans antigen were used. In addition, significant abnormalities in LMIF responding and stimulatory capacity were demonstrated in patients with Hodgkin's disease. LMIF production after stimulation with different agents allows for a better characterization of cellular defects in immunodeficiency disease.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 795576      PMCID： PMC1540992     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  14 in total

1.  MLC stimulatory capacity and production of blastogenic factor in patients with chronic lymphatic leukemia and Hodgkin's disease.

Authors:  S Kasakura
Journal:  Blood       Date:  1975-06       Impact factor: 22.113

2.  In vitro lymphocyte dysfunction in Hodgkin's disease.

Authors:  P R Graze; E Perlin; I Royston
Journal:  J Natl Cancer Inst       Date:  1976-02       Impact factor: 13.506

Review 3.  Malignant disease of the lymphoid system in immunological perspective.

Authors:  J A Hansen; R A Good
Journal:  Hum Pathol       Date:  1974-09       Impact factor: 3.466

4.  Partial characterization of leukocyte inhibitory factor by concanavalin A-stimulated human lymphocytes (LIF Con A).

Authors:  R E Rocklin
Journal:  J Immunol       Date:  1975-04       Impact factor: 5.422

5.  Leukocyte migration inhibitory factor (LMIF) induced by concanavalin A: standardized microassay for production in vitro.

Authors:  A J Górski; B Dupont; J A Hansen; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

6.  Cellular immunity in neoplasia. Antigen and mitogen responses in patients with bronchiogenic carcinoma.

Authors:  J C Rees; J L Rossio; H E Wilson; J P Minton; M C Dodd
Journal:  Cancer       Date:  1975-12       Impact factor: 6.860

7.  Lymphocyte abnormalities in untreated patients with Hodgkin's disease.

Authors:  G Holm; H Mellstedt; M Björkholm; B Johansson; D Killander; R Sundblad; G Söderberg
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

8.  Hodgkin's disease. An immunodepleting and immunosuppressive disorder.

Authors:  J J Twomey; A H Laughter; S Farrow; C C Douglass
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

9.  Lymphocyte transformation in vitro in patients with immunodeficiency diseases: use in diagnosis, histocompatibility testing and monitoring treatment.

Authors:  B Dupont; R A Good
Journal:  Birth Defects Orig Artic Ser       Date:  1975

10.  Studies on mediator production by highly purified human T and B lymphocytes.

Authors:  R E Rocklin; R P MacDermott; L Chess; S F Schlossman; J R David
Journal:  J Exp Med       Date:  1974-11-01       Impact factor: 14.307
View more
  2 in total

1.  The effect of uraemic "middle-sized molecules" on T lymphocyte functions.

Authors:  K Kálmán; L Löcsey; M Hauck; A Leövey
Journal:  Int Urol Nephrol       Date:  1980       Impact factor: 2.370

2.  Rationale for combined use of fetal liver and thymus for immunological reconstitution in patients with variants of severe combined immunodeficiency.

Authors:  R Pahwa; S Pahwa; R A Good; G S Incefy; R J O'Reilly
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.